Fig 3. SNS-032 reduced intestinal tumor number and burden in Ink4a/Arf-null Min mice.
Mice were treated as per Fig 1 except that DSS concentration was reduced to 3% for most mice, and SNS-032 dosing frequency was increased to 3x/wk. Tumor number (A) and burden (B) in each intestinal segment (as designated, from proximal (jejunum) to distal (colon)) per mouse was scored by an observer blinded to the treatment groups. SNS-032-treated mice had fewer tumors in the intestine as a whole (25% of carrier-treated mice, P < 0.001 for each intestinal segment and the intestine as a whole) and lower tumor burden (16% of the carrier-treated mice, P < 0.0001 for the intestine as a whole). The differences in tumor number and burden remained significant (P < 0.003 and P < 0.005, respectively) after exclusion of the 3 animals that received 4% DSS (carrier #1 and SNS-032-treated #1 and #2), which showed a preponderance of colon tumors.